Advertisement Ambry Genetics launches Fluidigm-based genomic research services - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Ambry Genetics launches Fluidigm-based genomic research services

Ambry Genetics has introduced Fluidigm BioMark HD and Access Array system-based genomic research services for gene expression, SNP genotyping and sample preparation for targeted sequencing.

The BioMark HD System provides the sensitivity required to study gene expression profiles down to the single-cell level and high throughput SNP genotyping and digital PCR for copy number variation and rare mutation detection.

The Access Array System will allow high-throughput, target-enrichment for the major next-generation sequencing instruments and allows users to enrich multiple unique targets from a large number of samples.

Ambry Genetics chief executive officer Charles Dunlop said: "We are ready to unleash the power of Fluidigm platforms and are anxious to offer our customers these enhanced capabilities."

Fluidigm president and chief executive officer Gajus Worthington said: "With the combined expertise, customer focus, and technological prowess of Fluidigm and Ambry, we are confident we wil deliver a new level of value to Ambry’s customers."